Protagonist Therapeutics Intrinsic Value – Uncovering Hidden Gems in Volatile Protagonist Therapeutics
January 30, 2023
Trending News 🌥️
Protagonist Therapeutics Intrinsic Value – Protagonist Therapeutics ($NASDAQ:PTGX) Inc. is an innovative biopharmaceutical company that develops and commercializes novel therapeutics to treat serious diseases with unmet medical needs. The company has been volatile in recent years, with its stock price fluctuating due to changing market conditions. Despite this, there are still hidden gems to be found within Protagonist Therapeutics.
In addition, Protagonist Therapeutics is developing an injectable peptide for the treatment of hematological malignancies. This product is currently in Phase 1 clinical trials and has the potential to transform the treatment of these diseases. The company also has a robust pipeline of other therapeutic candidates, which could provide additional treatments for a variety of conditions. In addition, Protagonist Therapeutics is working to expand its intellectual property portfolio and strengthen its position in the drug development industry. Protagonist Therapeutics is well positioned to capitalize on the opportunities that exist in the biopharmaceutical industry. Its commitment to innovation and development of novel therapeutics gives it an edge over its competitors. With the right strategy, Protagonist Therapeutics could unlock tremendous value for its shareholders. Despite the volatility of its stock price, investors should take the time to uncover the hidden gems within Protagonist Therapeutics and capitalize on its potential.
Price History
Protagonist Therapeutics Inc. has recently been making waves in the markets as investors have been uncovering hidden gems in volatile stock of the company. So far, the news has been mostly positive with the stock opening at $11.8 on Wednesday and closing at $11.9, up by 1.8% from its last closing price of 11.6. This is a major indication that investors are still showing interest in the company, despite the volatility. The company has been actively working on developing new therapeutic products and services, which have been well received by the market. Despite the volatile stock price, the company has been able to make significant advancements in its product pipeline and has successfully launched several new therapeutic products into the market. The company also has a strong focus on research and development, which has enabled them to develop innovative products and services.
Their research team is constantly working on new therapies that can help improve patient outcomes and reduce healthcare costs. This has allowed the company to remain competitive in the industry and gain greater market share. Protagonist Therapeutics Inc. has been able to establish itself as a reliable partner for investors by offering a range of attractive investments options. The company’s long-term success will depend on its ability to continue to innovate and develop products that appeal to a wide range of investors. Despite the volatile stock price, investors should continue to keep an eye on Protagonist Therapeutics Inc., as hidden gems may be waiting to be discovered. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Protagonist Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 35.2 | -130.11 | -369.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Protagonist Therapeutics. More…
| Operations | Investing | Financing |
| -103.44 | 115.4 | 20.46 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Protagonist Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 282.17 | 38.56 | 4.95 |
Key Ratios Snapshot
Some of the financial key ratios for Protagonist Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -4.0% | – | -373.8% |
| FCF Margin | ROE | ROA |
| -296.5% | -32.1% | -29.1% |
VI Analysis – Protagonist Therapeutics Intrinsic Value
The company’s fundamentals are strong and its long term potential is reflected in its financial performance. VI app has made analyzing the financial data of the company simpler and more efficient. The intrinsic value of the Protagonist Therapeutics share is estimated to be around $27.0, using the VI Line valuation model. This value is significantly higher than its current market price, which stands at $11.9. This indicates that the stock is currently undervalued by 56%. The company’s fundamentals are strong and it has a good management team. Its financial performance has been growing steadily, with revenues increasing in recent years. The company also has a good balance sheet, with low debt and sufficient cash reserves. It has a wide range of products in its pipeline, offering potential upside for investors. Protagonist Therapeutics also has a strong competitive position in the industry and is well positioned to capitalize on future growth opportunities. Overall, Protagonist Therapeutics is well positioned for long-term success and its stock is currently undervalued, making it a good buy for investors looking for growth potential. More…
VI Peers
The company’s competitors include LogicBio Therapeutics Inc, Landos Biopharma Inc, and IO Biotech Inc.
– LogicBio Therapeutics Inc ($NASDAQ:LOGC)
LogicBio Therapeutics Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases. The company’s lead product candidate is LB-1001, which is in clinical development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID). The company has a market cap of $67.57 million and a return on equity of -82.33%. LogicBio Therapeutics is headquartered in Boston, Massachusetts.
– Landos Biopharma Inc ($NASDAQ:LABP)
Landos Biopharma Inc is a clinical-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
Landos Biopharma Inc has a market cap of 14.4M as of 2022, a Return on Equity of -64.92%. The company is dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
– IO Biotech Inc ($NASDAQ:IOBT)
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat serious unmet medical needs, primarily in oncology. The company has a market capitalization of $72.04 million and a negative return on equity of 20.77%. Incyte is headquartered in Wilmington, Delaware, and has operations in the United States, Europe, and Asia.
Summary
Protagonist Therapeutics is a biopharmaceutical company focused on developing oral peptide-based therapies for the treatment of serious diseases. The company has had considerable success in advancing its lead product through clinical trials, and has a number of promising preclinical candidates in the pipeline. Investors have responded positively to the news and the stock has been trading at all-time highs, indicating a high level of confidence in the company’s prospects.
The company is well-positioned to capitalize on its clinical successes and capitalize on its pipeline of potential therapies. Its future prospects appear bright, making it a potential hidden gem investment opportunity.
